Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: Validating Runx2 as a potential antimetastatic drug screening platform

Clinical Cancer Research

Volumn 15, Issue 13, 2009, Pages 4322-4335

  Chua, Chee Wai ^a   Chiu, Yung Tuen ^a   Yuen, Hiu Fung ^a   Chan, Kwok Wah ^a   Man, Kwan ^a   Wang, Xianghong ^a   Ling, Ming Tat ^a   Wong, Yong Chuan ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CADHERIN; COLLAGEN TYPE 1; FINGOLIMOD; PROTEIN KINASE B; TRANSCRIPTION FACTOR RUNX2;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL ASSAY; CELL INVASION; CELL STRAIN PC 3; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS INHIBITION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; TRANSCRIPTION REGULATION;

AGED; AGED, 80 AND OVER; ANDROGENS; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROPYLENE GLYCOLS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; SPHINGOSINE; TUMOR CELLS, CULTURED;

EID: 67650369580     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3157     Document Type: Article

References (50)

1. Jemal A, Siegel R,Ward E, et al. Cancer statistics, 2008. CA CancerJClin 2008;58:71-96.
2. Hsing AW, Tsao L, Devesa SS. Internationaltre nds and patterns of prostate cancer incidence andmortality. IntJCancer 2000;85:60-7.
3. Denmeade SR, IsaacsJT. Ahistory of prostate cancer treatment. Nat Rev Cancer 2002;2:389-96.
4. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
5. Logothetis CJ, Lin,SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005;5: 21-8.
6. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999; 39:246-61.
7. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptionalact ivator of osteoblast differentiation. Cell1997;89:747-54.
8. Blyth K, Cameron ER, NeilJC.The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer 2005;5: 376-87.
9. Pratap J, Javed A, Languino LR, et al. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. MolC ellB iol2 005;25: 8581-91.
10. Brubaker KD,Vessella RL, Brown LG, Corey E.Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 2003;56:13- 22.
11. Blyth K,Vaillant F, Hanlon L, et al. Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo. Cancer Res 2006;66:2195-201.
12. ShinomiyaT, Li XK,AmemiyaH, Suzuki S. Animmunosuppressive agent, FTY720, increases intracellular concentration of calcium ion and induces apoptosis in HL-60. Immunology1997;91:594-600.
13. MatsudaT, Nakajima H, Fujiwara I, Mizuta N, OkaT. Caspase requirement for the apoptotic death of WR19L-induced by FTY720. Transplant Proc 1998; 30:2355-7.
14. Sonoda Y, Yamamoto D, Sakurai S, et al. FTY720, a novelimmunosuppressive agent, induces apoptosis in human glioma cells. Biochem Biophys Res Commun 2001;281:282-8.
15. LeeTK, Man K, Ho JW, et al. FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma. Clin Cancer Res 2005;11:8458-66.
16. Azuma H,Takahara S, Ichimaru N, et al.Marked prevention of tumor growth and metastasis by a novelimmunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res 2002;62:1410- 9.
17. Azuma H, Takahara S, Horie S, Muto S, Otsuki Y, Katsuoka Y. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. JUrol20 03;169:2372-7.
18. WangJD,Takahara S, Nonomura N, et al. Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation. Prostate 1999;40:50-5.
19. ChuaCW, LeeDT, LingMT, et al . FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer. Int J Cancer 2005;117: 1039-48.
20. Zhou C, Ling MT, Kin-Wah LT, Man K,Wang X, WongYC. FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase. Cancer Lett 2006;233:36-47.
21. KwokWK, Ling MT, LeeTW, et al. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 2005;65:5153-62.
22. PeinadoH,OlmedaD, CanoA. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelialphenotype?NatRevCancer2007;7:415- 28.
23. HechtJ, SeitzV, Urban M, et al . Detection of novel skeletogenesis target genes by comprehensive analysis of a Runx2(-/-) mouse model. Gene Expr Patterns 2007;7:102-12.
24. Knerr K, Ackermann K, Neidhart T, PyerinW. Bone metastasis: Osteoblasts affect growth and adhesion regulons in prostate tumor cells and provoke osteomimicry. Int JCancer 2004;111:152-9.
25. FujitaT, AzumaY, Fukuyama R, et al. Runx2 induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3K-Akt signaling. JCell Biol 2004;166:85- 95.
26. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histologicalgrad ing and clinical staging. J Urol 1974;111: 58-64.
27. Miyamoto KK, McSherry SA, Dent GA, et al. Immunohistochemistry of the androgen receptor in human benign and malignant prostate tissue. J Urol 1993; 149:1015 - 9.
28. Ducy P, KarsentyG.Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene.MolCe llB iol 1995;15:1858-69.
29. LingMT, LauTC, Zhou C, et al . Overexpression of Id-1 in prostate cancer cells promotes angiogenesis through the activation of vascular endothelial growth factor (VEGF). Carcinogenesis 2005;26:1668-76.
30. D'Ippolito G, Diabira S, Howard GA,Menei P, Roos BA, Schiller PC. Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatalyo ung and old human cells with extensive expansion and differentiation potential. J Cell Sci 2004; 117:2971 - 81.
31. Debiais F, Lemonnier J, Hay E, Delannoy P, Caverzasio J, Marie PJ. Fibroblast growth factor-2 (FGF-2) increases N-cadherin expression through protein kinase C and Src-kinase pathways in human calvaria osteoblasts. JCellBiochem2001;81:68-81.
32. Oda T, Kanai Y, Oyama T, et al. E-cadherin gene mutations in human gastric carcinoma cell lines. Proc NatlAc ad Sci US A1994;91:1858-62.
33. Bracke ME, BoterbergT, BruyneelE A, MareelMM. Collagen invasion assay. In: Brooks SA, Schumacher U, editors. Metastasis research protocols. Totowa (NJ): Humana Press; 2001. p. 81-9.
34. Zagars GK, Pollack A, Kavadi VS, von Eschenbach AC. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat OncolB iolP hys1995;32:293-306.
35. D'Amico AV,Whittington R, Malkowicz SB, et al. Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure. Urology 1997;49:23 - 30.
36. Algan O, Pinover WH, Hanlon AL, Al-Saleem TI, Hanks GE. Is there a subset of patients with PSA > or = 20 ng/mL who do wella fter conformalbeamradiotherapy? Radiat OncolI nvestig 1999;7:106 -10.
37. ZayzafoonM, Abdulkadir SA, McDonaldJM. Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines. J Biol Chem 2004;279:3662-70.
38. Xiao G, Jiang D,Thomas P, et al. MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J BiolC hem 2000;275: 4453-9.
39. Tomita K, van BA, van Leenders GJ, et al. Cadherin switching in human prostate cancer progression.Cancer Res 2000;60:3650-4.
40. JaggiM, NazemiT, Abrahams NA, et al.N-cadherin switching occurs in high Gleason grade prostate cancer. Prostate 2006;66:193-9.
41. GravdalK, Halvorsen OJ, Haukaas SA, Akslen LA. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res 2007;13: 7003-11.
42. Di Lullo GA, Sweeney SM, Korkko J, la-Kokko L, San Antonio JD. Mapping the ligand-binding sites and disease-associated mutations on the most abundant protein in the human, type I collagen. JBiol Chem 2002;277:4223-31.
43. Li L, Ittmann MM, Ayala G, et al.The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis 2005;8:108-18.
44. Aberg T,Wang XP, Kim JH, et al. Runx2 mediates FGF signaling from epithelium to mesenchyme during tooth morphogenesis. Dev Biol20 04;270:76-93.
45. Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR. Cadherin switching. J Cell Sci 2008; 121:727 - 35.
46. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenicmouse. Proc NatlAcad Sci US A1995;92:3439-43.
47. Kaplan-Lefko PJ, Chen TM, Ittmann MM, et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003; 55:219-37.
48. Kim MJ, Bhatia-Gaur R, Banach-Petrosky WA, et al. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res 2002;62: 2999-3004.
49. Abate-Shen C, Banach-PetroskyWA, Sun X, et al. Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res 2003;63:3886-90.
50. Javed A, Barnes GL, Pratap J, et al. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc NatlAca d Sci U S A 2005; 102:1454 - 9.